Cat. #154729
Anti-cErbB2/HER2 [3B5]
Cat. #: 154729
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: cErbB2/HER-2
Class: Monoclonal
Application: IHC ; IF ; IP ; WB
Reactivity: Human ; Mouse ; Rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Netherlands Cancer Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-cErbB2/HER2 [3B5]
- Alternate name: NEU
- Research fields: Cancer;Cell signaling and signal transduction
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 185 kDa
- Strain: Balb/c
- Reactivity: Human ; Mouse ; Rat
- Host: Mouse
- Application: IHC ; IF ; IP ; WB
- Description: HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients
- Immunogen: Mouse immunized with a synthetic peptide TAENPEYLGLDVPV corresponding to amino acid residues
- Isotype: IgG1
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: cErbB2/HER-2
- Molecular weight: 185 kDa
- Target background: HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients
Applications
- Application: IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -20° C
- Shipping conditions: Shipping at 4° C
References
- Ttu et al. 1994. Cancer. 73(9):2359-65. PMID: 7909490.
- Marks et al. 1994. Ann Surg. 219(4):332-41. PMID: 7909221.
- van Leeuwen et al. 1990. Oncogene. 5(4):497-503. PMID: 1970152.
- van de Vijver et al. 1988. N Engl J Med. 319(19):1239-45. PMID: 2903446.
- Varley et al. 1987. Oncogene. 1(4):423-30. PMID: 3330785.
- Di Fiore et al. 1987. Science. 237(4811):178-82. PMID: 2885917.
- Slamon et al. 1987. Science. 235(4785):177-82. PMID: 3798106.
- Yamamoto et al. 1986. Nature. 319(6050):230-4. PMID: 3003577.
- Bargmann et al. 1986. Nature. 319(6050):226-30. PMID: 3945311.
- Blick et al. 1984. Blood. 64(6):1234-9. PMID: 6208953.
